When MultiCare peer support liaison Chandelle Gill speaks to a patient about their addiction, she can see herself.

Phase Inpatient Withdrawal Programme for Long-Term Opioid Use in Non-Cancer Pain,” published in the March 2025 issue of ...

A new study from University of Toronto Engineering researchers points to practical strategies to prevent deaths from opioid ...

Kentucky Gov. Andy Beshear referred to conversion therapy as "torture." His Republican counterparts may ignore his newest ...

In this systematic review, evidence for the efficacy of acute pain interventions on individuals with opioid use disorder was ...

Weill Cornell Medicine researchers found that restricting telehealth prescriptions for opioid use disorder could keep thousands from accessing buprenorphine, a medication that helps people recover ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, ...

If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years Published ...

A plan for the future of housing in Victoria, including allowing four-storey projects in most areas, and six-storey and taller projects in strategic locations, will be on the table at Thursday’s ...

Nature, online article titled: US drug agency approves potent painkiller the first non-opioid in decades. The FDA's nod for suzetrigine bolsters confidence in the pharmaceutical industry's ...

marking a significant advancement in the treatment of moderate to severe opioid use disorder. See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and ...